News | Magnetic Resonance Imaging (MRI) | March 15, 2017

Toshiba Vantage Galan 3T MRI Tapped for UCI Brain Trauma Research

Study seeks to identify precursors to CTE in high school football players

UCI, University of California Irvine, brain trauma research, CTE, Toshiba, Vantage Galan 3T MRI

March 15, 2017 — Researchers at the University of California Irvine now have access to Toshiba Medical’s most advanced magnetic resonance (MR) technology for their cutting-edge neurology work investigating cerebral microbleeds (CMB) in high school football players as a potential precursor to chronic traumatic encephalopathy (CTE). As part of its ongoing, first-of-its-kind study to identify early signs of brain trauma in young athletes, UCI doctors will now leverage Toshiba Medical’s Vantage Galan 3T MR system as a key diagnostic tool.

“Young athletes competing in high-impact activities face many potential risks of head injury, but Toshiba Medical’s Galan 3T MR system may enable us to identify these risks and make greater strides in our understanding and treatment of early head trauma,” said Mark Fisher, M.D., UCI professor of neurology and study lead researcher. “We are very excited at the prospect of marrying healthcare and technology to provide better treatment for athletes today and improved preventative care in the years to come.”

The UCI study is investigating the use of non-contrast MRI as a safe and noninvasive way to examine young athletes and other patients for early signs of CTE, a degenerative disease found in those who suffer head trauma, and a well-documented consequence of sub-concussive head injury. Evaluations of local high school student volunteers include 100 test subjects (football players) and 50 control subjects (non-football players), and the research is supported by the UCI Exercise Medicine and Sport Sciences Initiative (EMSSI). Toshiba Medical has provided application training to UCI researchers to operate the Vantage Galan 3T. UCI is also leveraging the system for imaging of the cervical spine to screen for early neck injury.

The Vantage Galan 3T was chosen for its ability to conduct quick, comfortable and high-quality neuro exams. Designed to increase signal-to-noise ratio (SNR) by up to 20 percent, the system allows for faster sampling and higher resolution images thanks to PURERF and Saturn technologies. This, combined with the ability to stack protocol sequences, results in quick neuro exams enabling researchers to produce higher resolution images for myriad neuro exams in under five minutes. The system’s 71 cm aperture expands access to large and claustrophobic patients, while Pianissimo Zen technology reduces sound during acquisition by 99 percent.

For more information: www.medical.toshiba.com

Related Content

high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017
EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity...
lung cancer recurrence, biomarker blood test, CT scans, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study
News | Lung Cancer | March 28, 2017
Results from a prospective clinical trial showed a blood test looking at specific biomarkers was able to detect lung...
VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017
March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation treatmen
proton therapy, recurrent lung cancer, clinical study, IMPT, 2017 Multidisciplinary Thoracic Cancers Symposium
News | Proton Therapy | March 24, 2017
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for...
Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroN
News | Prostate Cancer | March 22, 2017
Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to...
lung cancer, radiation therapy, immune checkpoint inhibitors, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study
News | Lung Cancer | March 22, 2017
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs)...
diffusion weighted MRI, children, traumatic brain injury, TBI recovery, Neurology journal study
News | Magnetic Resonance Imaging (MRI) | March 21, 2017
A new imaging biomarker may help predict which children will take longer to recover from a traumatic brain injury (TBI...
SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely...
PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017
The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates...
Overlay Init